by Sam Tetlow | Aug 27, 2021 | Funding Strategies, Funding Your R&D
NIH_Topics_for_Budget_WaiversDownload Every funding period, NIH announces topics approved for budgets greater than $259,613 for Phase I SBIR/STTR awards, and greater than $1,730,751 for Phase II, presenting a lucrative opportunity for businesses. That being said, NIH...
by Julie Fife | Jun 15, 2021 | Funding Strategies, Funding Your R&D, Grant Writing Partner
When trying to secure non-dilutive funding, organizations are faced with a big decision – to write and submit the grant themselves or to partner with a grant writing company? The right grant writing company serves many purposes outside of actually writing and...
by Sam Tetlow | Apr 6, 2021 | Applying for Grant, Funding Your R&D, Non-Dilutive Financing, Non-Dilutive Funds
Non-dilutive funding is financing that does require any sales of your shares, so it does not dilute the value of existing shares or equity. In other words, it allows you to keep your company equity in place. Non-dilutive funding protects your equity and profits while...
by Sam Tetlow | Mar 11, 2021 | Funding Programs, Funding Strategies, Funding Your R&D, Grant Writing Partner, Grantsmanship, Non-Dilutive Funds, SBIR (Small Business Innovative Research)
March is Women’s History Month! Grant Engine wants to see women-owned small businesses succeed in securing funding, so we put this list of resources together in support of female entrepreneurs. The NIH, especially the SBIR/STTR programs, shares this mission. The SBIR...
by Sam Tetlow | Aug 13, 2020 | Funding Strategies, Funding Your R&D
NIH_Topics_for_Budget_WaiversDownload Every funding period, NIH announces topics approved for budgets greater than $256,580 for Phase I SBIR/STTR awards, and greater than $1,710,531 for Phase II, presenting a lucrative opportunity for businesses. That being said, NIH...
by Sam Tetlow | Mar 26, 2020 | Funding Programs, Funding Strategies, Funding Your R&D, Non-Dilutive Financing, Non-Dilutive Funds
NIH has provided guidance outlining the flexibilities available to recipients conducting NIH-funded clinical trials and human subject studies, that are impacted by the declared public health emergency for COVID-19. If unanticipated costs are identified due to impacts...
Recent Comments